Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial
Abstract Posterolateral spinal fusion is the standard surgical approach for patients with degenerative disc disease. In our previously published article, we reported a 5-years follow-up of a phase I/II clinical trial in patients undergoing spinal fusion with autologous mesenchymal stem cells (MSCs)...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-04-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-023-03298-4 |
| _version_ | 1827966432167591936 |
|---|---|
| author | Victoria Gomez-Ruiz Juan F. Blanco Eva M. Villarón Helena Fidalgo Miriam López-Parra Fermín Sánchez-Guijo |
| author_facet | Victoria Gomez-Ruiz Juan F. Blanco Eva M. Villarón Helena Fidalgo Miriam López-Parra Fermín Sánchez-Guijo |
| author_sort | Victoria Gomez-Ruiz |
| collection | DOAJ |
| description | Abstract Posterolateral spinal fusion is the standard surgical approach for patients with degenerative disc disease. In our previously published article, we reported a 5-years follow-up of a phase I/II clinical trial in patients undergoing spinal fusion with autologous mesenchymal stem cells (MSCs) embedded in tricalcium phosphate. In the current manuscript, we have updated the results with a 10-year follow-up, the longest reported to date in this setting. After clinical and radiological evaluation, safety of the procedure was further confirmed in all 11 treated patients, with no evidence of tumor, infection, inflammatory reaction, or heterotopic ossification related to the administration of MSCs. Regarding clinical efficacy, low back pain and radicular pain (both assessed by the visual analogue scale—VAS), and the Owestry Disability Index remained significantly lower compared to pre-intervention. Radiologic evaluation demonstrated spinal fusion in all cases, improving over time. Finally, quality of life improved significantly also during follow-up. In summary, the use of tricalcium phosphate-embedded autologous MSCs with lumbar posterolateral arthrodesis is safe and potentially provides long-term benefits for 10 years. |
| first_indexed | 2024-04-09T17:49:54Z |
| format | Article |
| id | doaj.art-f81f145a3cd74156b8b313a697035b90 |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-04-09T17:49:54Z |
| publishDate | 2023-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-f81f145a3cd74156b8b313a697035b902023-04-16T11:08:17ZengBMCStem Cell Research & Therapy1757-65122023-04-011411310.1186/s13287-023-03298-4Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trialVictoria Gomez-Ruiz0Juan F. Blanco1Eva M. Villarón2Helena Fidalgo3Miriam López-Parra4Fermín Sánchez-Guijo5Department of Orthopedic Surgery, IBSAL-University Hospital of SalamancaDepartment of Orthopedic Surgery, IBSAL-University Hospital of SalamancaCell Therapy Area, Department of Hematology, IBSAL-University Hospital of SalamancaDepartment of Orthopedic Surgery, IBSAL-University Hospital of SalamancaCell Therapy Area, Department of Hematology, IBSAL-University Hospital of SalamancaCell Therapy Area, Department of Hematology, IBSAL-University Hospital of SalamancaAbstract Posterolateral spinal fusion is the standard surgical approach for patients with degenerative disc disease. In our previously published article, we reported a 5-years follow-up of a phase I/II clinical trial in patients undergoing spinal fusion with autologous mesenchymal stem cells (MSCs) embedded in tricalcium phosphate. In the current manuscript, we have updated the results with a 10-year follow-up, the longest reported to date in this setting. After clinical and radiological evaluation, safety of the procedure was further confirmed in all 11 treated patients, with no evidence of tumor, infection, inflammatory reaction, or heterotopic ossification related to the administration of MSCs. Regarding clinical efficacy, low back pain and radicular pain (both assessed by the visual analogue scale—VAS), and the Owestry Disability Index remained significantly lower compared to pre-intervention. Radiologic evaluation demonstrated spinal fusion in all cases, improving over time. Finally, quality of life improved significantly also during follow-up. In summary, the use of tricalcium phosphate-embedded autologous MSCs with lumbar posterolateral arthrodesis is safe and potentially provides long-term benefits for 10 years.https://doi.org/10.1186/s13287-023-03298-4Mesenchymal stem cellsSpinal fusionBone graftIntervertebral disc degenerationCell transplantation |
| spellingShingle | Victoria Gomez-Ruiz Juan F. Blanco Eva M. Villarón Helena Fidalgo Miriam López-Parra Fermín Sánchez-Guijo Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial Stem Cell Research & Therapy Mesenchymal stem cells Spinal fusion Bone graft Intervertebral disc degeneration Cell transplantation |
| title | Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial |
| title_full | Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial |
| title_fullStr | Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial |
| title_full_unstemmed | Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial |
| title_short | Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial |
| title_sort | autologous mesenchymal stem cell transplantation for spinal fusion 10 years follow up of a phase i ii clinical trial |
| topic | Mesenchymal stem cells Spinal fusion Bone graft Intervertebral disc degeneration Cell transplantation |
| url | https://doi.org/10.1186/s13287-023-03298-4 |
| work_keys_str_mv | AT victoriagomezruiz autologousmesenchymalstemcelltransplantationforspinalfusion10yearsfollowupofaphaseiiiclinicaltrial AT juanfblanco autologousmesenchymalstemcelltransplantationforspinalfusion10yearsfollowupofaphaseiiiclinicaltrial AT evamvillaron autologousmesenchymalstemcelltransplantationforspinalfusion10yearsfollowupofaphaseiiiclinicaltrial AT helenafidalgo autologousmesenchymalstemcelltransplantationforspinalfusion10yearsfollowupofaphaseiiiclinicaltrial AT miriamlopezparra autologousmesenchymalstemcelltransplantationforspinalfusion10yearsfollowupofaphaseiiiclinicaltrial AT ferminsanchezguijo autologousmesenchymalstemcelltransplantationforspinalfusion10yearsfollowupofaphaseiiiclinicaltrial |